E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/25/2023 in the Prospect News Structured Products Daily.

New Issue: GS Finance sells $10 million contingent income buffered notes on biotech ETF

Chicago, Oct. 25 – GS Finance Corp. priced $10 million of contingent income buffered autocallable securities due Oct. 21, 2024 tied to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.

The notes are guaranteed by Goldman Sachs Group, Inc.

The notes will pay a 19.2% contingent quarterly coupon if the ETF closes above its 90% buffer price on the related observation date. Previously unpaid coupons will also be paid.

The notes will be automatically called on any quarterly observation date if the ETF closes above its initial level.

Investors will receive par if the ETF finishes above its 90% buffer level.

Otherwise, investors will lose 1.1111% for each 1% decline beyond the 10% buffer.

Goldman Sachs & Co. LLC is the agent.

Issuer:GS Finance Corp.
Guarantor:Goldman Sachs Group, Inc.
Issue:Contingent income buffered autocallable securities
Underlying ETF:SPDR S&P Biotech
Amount:$10,000,000
Maturity:Oct. 21, 2024
Coupon:19.2% annual rate, payable quarterly if ETF closes above buffer level on related observation date; previously unpaid coupons will also be paid
Price:Par
Payout at maturity:Par if ETF finishes above buffer level; otherwise, 1.1111% for each 1% decline beyond 10% buffer
Call:At par on any quarterly observation date if ETF closes above initial level
Initial value:$69.60
Buffer value:90% of initial level
Pricing date:Oct. 18
Settlement date:Oct. 23
Agent:Goldman Sachs & Co. LLC
Fees:0.1%
Cusip:40057WR90

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.